Targeting treatment resistance: unveiling the potential of RNA methylation regulators and TG-101,209 in pan-cancer neoadjuvant therapy
This study emphasizes the pivotal role of RMRs in pan-cancer neoadjuvant therapy, serving as predictive biomarkers for monitoring the tumor microenvironment, patient prognosis, and therapeutic response. Distinct molecular subtypes of RMRs aid individualized stratification in neoadjuvant therapy. Combining TG-101,209 adjuvant therapy presents a promising strategy to enhance the sensitivity of high-RMR-expressing tumors to chemotherapy and immunotherapy. However, further validation studies are necessary to fully understand the clinical utility of RNA methylation regulators and their impact on patient outcomes.
Authors
- Yongjie Xie (ORCID: https://orcid.org/0009-0003-3595-0866)
- Jing Zhao (ORCID: https://orcid.org/0000-0002-4520-6307)
- Ziyun Liu (ORCID: https://orcid.org/0000-0002-4999-0135)
- Xiangyu Liu
- Jie Zhang (ORCID: https://orcid.org/0000-0003-1587-503X)
- Rui Li (ORCID: https://orcid.org/0000-0001-5343-3027)
- Xia Zhang (ORCID: https://orcid.org/0000-0002-9040-1486)
- Li Bao (ORCID: https://orcid.org/0000-0002-6436-1492)
- Zhenyu Shi (ORCID: https://orcid.org/0000-0002-5050-4800)
- Yaoyao Zhou (ORCID: https://orcid.org/0000-0001-5104-0457)
- Gong Cheng (ORCID: https://orcid.org/0000-0002-6692-7824)
- Bin Li
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1186/s13046-024-03111-x
- Citations
- 5
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- National Natural Science Foundation of China